Total Payments
$290,268
2024 Payments
$48,047
Companies
29
Transactions
291
Medicare Patients
1,661
Medicare Billing
$388,451
Payment Breakdown by Category
Consulting$168,263 (58.0%)
Other$59,948 (20.7%)
Research$33,052 (11.4%)
Travel$21,819 (7.5%)
Food & Beverage$7,030 (2.4%)
Education$156.05 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $168,263 | 67 | 58.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,328 | 14 | 18.0% |
| Unspecified | $33,052 | 13 | 11.4% |
| Travel and Lodging | $21,819 | 76 | 7.5% |
| Food and Beverage | $7,030 | 113 | 2.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,620 | 1 | 1.6% |
| Honoraria | $3,000 | 1 | 1.0% |
| Education | $156.05 | 6 | 0.1% |
Payments by Type
General
$257,215
278 transactions
Research
$33,052
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $113,317 | 105 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $38,100 | 22 | $0 (2021) |
| ABBVIE INC. | $29,338 | 18 | $0 (2022) |
| Merck Sharp & Dohme LLC | $16,693 | 27 | $0 (2023) |
| Advanced Accelerator Applications | $15,586 | 5 | $0 (2021) |
| Halozyme Inc | $8,386 | 20 | $0 (2019) |
| Eisai Inc. | $8,257 | 11 | $0 (2024) |
| PFIZER INC. | $7,540 | 8 | $0 (2024) |
| Lilly USA, LLC | $6,274 | 7 | $0 (2019) |
| Ipsen Pharma SAS | $6,090 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,047 | 43 | Ipsen Biopharmaceuticals, Inc ($23,940) |
| 2023 | $20,910 | 18 | Ipsen Biopharmaceuticals, Inc ($13,207) |
| 2022 | $20,900 | 13 | ABBVIE INC. ($6,413) |
| 2021 | $21,000 | 7 | Novartis Pharmaceuticals Corporation ($8,750) |
| 2020 | $38,036 | 28 | Ipsen Biopharmaceuticals, Inc ($18,143) |
| 2019 | $41,241 | 61 | Ipsen Biopharmaceuticals, Inc ($22,163) |
| 2018 | $37,790 | 53 | Ipsen Biopharmaceuticals, Inc ($15,205) |
| 2017 | $62,343 | 68 | Novartis Pharmaceuticals Corporation ($18,667) |
All Payment Transactions
291 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,960.00 | General |
| 12/23/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug), Nubeqa | Consulting Fee | Cash or cash equivalent | $1,140.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,525.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $531.06 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $523.31 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Food and Beverage | In-kind items and services | $330.75 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Travel and Lodging | In-kind items and services | $214.77 | General |
| Category: Oncology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 10/31/2024 | PFIZER INC. | — | — | In-kind items and services | $620.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 10/31/2024 | PFIZER INC. | — | — | In-kind items and services | $620.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 10/01/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $343.00 | General |
| 09/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,045.00 | General |
| Category: Oncology | ||||||
| 08/10/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $5.13 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PONSEGROMAB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 07/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,835.00 | General |
| 06/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,046.50 | General |
| Category: Oncology | ||||||
| 06/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $669.87 | General |
| Category: Oncology | ||||||
| 06/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $379.63 | General |
| Category: Oncology | ||||||
| 06/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $164.83 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,220.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH LUTATHERA RESEARCH | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
| A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) | ABBVIE INC. | $6,413 | 1 |
| PONSEGROMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Phase I feasibility study of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer and cholestatic hyperbilirubinaemia (PANCHO) (AX-CL-PANC-PI-008519) | Celgene Corporation | $2,866 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,180 | 3 |
| AX-CL-PANC-PI-008519 - Phase I feasibility study of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer and cholestatic hyperbilirubinaemia (PANCHO) | Celgene Corporation | $1,524 | 1 |
| Phase III Study - PANC-003 (BMS Study Number: CA139-P15) (ABI-007-PANC-003) | Celgene Corporation | $476.00 | 1 |
| PF06946860 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 380 | 1,085 | $364,099 | $90,642 |
| 2022 | 6 | 441 | 1,232 | $411,306 | $104,115 |
| 2021 | 7 | 435 | 1,275 | $388,400 | $109,304 |
| 2020 | 6 | 405 | 1,207 | $325,906 | $84,391 |
Total Patients
1,661
Total Services
4,799
Medicare Billing
$388,451
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 207 | 817 | $263,246 | $64,834 | 24.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 55 | 142 | $34,518 | $9,430 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 59 | 59 | $35,802 | $8,742 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 44 | 52 | $24,208 | $6,095 | 25.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $6,325 | $1,541 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 203 | 844 | $270,362 | $68,239 | 25.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 73 | 200 | $45,994 | $12,015 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 74 | 74 | $44,132 | $11,065 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 66 | 83 | $39,332 | $9,989 | 25.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 19 | $6,269 | $1,657 | 26.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 12 | $5,217 | $1,150 | 22.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 198 | 911 | $265,458 | $76,211 | 28.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 81 | 204 | $47,679 | $12,626 | 26.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 68 | 68 | $39,254 | $10,791 | 27.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 44 | $18,680 | $5,171 | 27.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 21 | $9,276 | $2,349 | 25.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 15 | $5,001 | $1,339 | 26.8% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Facility | 2021 | 12 | 12 | $3,052 | $816.24 | 26.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 187 | 811 | $207,626 | $52,903 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 88 | 261 | $61,335 | $16,496 | 26.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 54 | 54 | $29,592 | $7,701 | 26.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 35 | 36 | $12,996 | $3,300 | 25.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 24 | 26 | $11,544 | $3,141 | 27.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 17 | 19 | $2,813 | $849.80 | 30.2% |
About Andrew Hendifar, MD, MPH
Andrew Hendifar, MD, MPH is a Internal Medicine healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1649473414.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Andrew Hendifar, MD, MPH has received a total of $290,268 in payments from pharmaceutical and medical device companies, with $48,047 received in 2024. These payments were reported across 291 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($168,263).
As a Medicare-enrolled provider, Hendifar has provided services to 1,661 Medicare beneficiaries, totaling 4,799 services with total Medicare billing of $388,451. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location West Hollywood, CA
- Active Since 06/07/2007
- Last Updated 02/22/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649473414
Products in Payments
- Onivyde (Drug) $58,490
- ONIVYDE (Drug) $29,783
- AFINITOR (Drug) $25,846
- LUTATHERA (Drug) $23,536
- SOMATULINE DEPOT (Drug) $18,382
- Creon (Drug) $17,065
- KEYTRUDA (Biological) $10,797
- CREON (Drug) $6,413
- CYRAMZA (Drug) $5,924
- Abraxane (Drug) $5,355
- MK-7339 (Drug) $5,354
- Lenvima (Drug) $5,132
- CABOMETYX (Drug) $4,557
- Xermelo (Drug) $3,742
- SANDOSTATIN LAR (Drug) $3,469
- Dayvigo (Drug) $3,125
- Somatuline Depot (Drug) $1,789
- Lonsurf (Drug) $1,325
- Nplate (Biological) $1,298
- IMFINZI (Drug) $1,198
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in West Hollywood
Anthony Mills, Md, MD
Internal Medicine — Payments: $510,976
Internal Medicine $510,976
Dr. Michael Shehata, M.d, M.D
Internal Medicine — Payments: $279,189
Internal Medicine $279,189
Dr. Stanley Jordan, Md, MD
Internal Medicine — Payments: $201,443
Internal Medicine $201,443
Dr. Barham Abu Dayyeh, Md, MD
Internal Medicine — Payments: $173,790
Internal Medicine $173,790
Dr. Rabindra Watson, M.d, M.D
Internal Medicine — Payments: $157,237
Internal Medicine $157,237
Phillip Gu, Md, MD
Internal Medicine — Payments: $80,698
Internal Medicine $80,698